Prostaglandin E2

Prostaglandin E 2 (PGE 2 ), also known as dinoprostone, is a naturally occurring prostaglandin with oxytocic properties that is used as a medication.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 7 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Prostaglandin E 2 (PGE 2 ), also known as dinoprostone, is a naturally occurring prostaglandin with oxytocic properties that is used as a medication. Dinoprostone is used in labor induction, bleeding after delivery, termination of pregnancy, and in newborn babies to keep the ductus arteriosus open.

In babies it is used in those with congenital heart defects until surgery can be carried out. It is also used to manage gestational trophoblastic disease. It may be used within the vagina or by injection into a vein.

PGE 2 synthesis within the body begins with the activation of arachidonic acid (AA) by the enzyme phospholipase A 2 . Once activated, AA is oxygenated by cyclooxygenase (COX) enzymes to form prostaglandin endoperoxides. Specifically, prostaglandin G 2 (PGG 2 ) is modified by the peroxidase moiety of the COX enzyme to produce prostaglandin H 2 (PGH 2 ) which is then converted to PGE 2 .

Common side effects of PGE 2 include nausea, vomiting, diarrhea, fever, and excessive uterine contraction. In babies there may be decreased breathing and low blood pressure. Caution should be taken in people with asthma or glaucoma and it is not recommended in those who have had a prior C-section.

It works by binding and activating the prostaglandin E 2 receptor which results in the opening and softening of the cervix and dilation of blood vessels.…

Prostaglandin E 2 (PGE 2 ), also known as dinoprostone, is a naturally occurring prostaglandin with oxytocic properties that is used as a medication. Dinoprostone is used in labor induction, bleeding after delivery, termination of pregnancy, and in newborn babies to keep the ductus arteriosus open.

In babies it is used in those with congenital heart defects until surgery can be carried out. It is also used to manage gestational trophoblastic disease. It may be used within the vagina or by injection into a vein.

PGE 2 synthesis within the body begins with the activation of arachidonic acid (AA) by the enzyme phospholipase A 2 . Once activated, AA is oxygenated by cyclooxygenase (COX) enzymes to form prostaglandin endoperoxides. Specifically, prostaglandin G 2 (PGG 2 ) is modified by the peroxidase moiety of the COX enzyme to produce prostaglandin H 2 (PGH 2 ) which is then converted to PGE 2 .

Common side effects of PGE 2 include nausea, vomiting, diarrhea, fever, and excessive uterine contraction. In babies there may be decreased breathing and low blood pressure. Caution should be taken in people with asthma or glaucoma and it is not recommended in those who have had a prior C-section.

It works by binding and activating the prostaglandin E 2 receptor which results in the opening and softening of the cervix and dilation of blood vessels. Prostaglandin E 2 was first synthesized in 1969 by E.J. Corey and approved for medical use by the FDA in the United States in 1977. It is on the World Health Organization's List of Essential Medicines.

Prostaglandin E 2 works as well as prostaglandin E 1 in babies.

Physiological effects

Dinoprostone has important effects in labor by inducing softening of the cervix and causing uterine contraction, and also stimulates osteoblasts to release factors that stimulate bone resorption by osteoclasts. Natural prostaglandins, including PGE 1 and PGE 2 , are important in the structure and function of the ductus arteriosus in fetuses and newborns.

They allow the ductus arteriosus to remain open, providing the necessary connection between the pulmonary artery and descending aorta that allows the blood to bypass the fetus's underdeveloped lungs and be transported to the placenta for oxygenation. The ductus arteriosus normally begins to close upon birth due to an increase of PGE 2 metabolism, but in newborns with congenital heart disease, prostaglandins can be used to keep the ductus arteriosus open longer than normal to sustain healthy oxygen saturation levels in the blood.

Although PGE 1 is more commonly used in this setting, there has been a report of oral PGE 2 being used to treat ductus-dependent congenital heart diseases in newborns to delay surgical treatment until the pulmonary arteries grew. In addition, PGE 2 was used in another report to dilate the ductus arteriosus in newborns with various cardiovascular defects to allow for better perfusion of the lungs and kidneys.

On the other hand, the post-partal synthesis of PGE 2 in newborns is considered one cause of patent ductus arteriosus. When administered in aerosol form, PGE 2 serves as a bronchodilator, but its use in this setting is limited by the fact that it also causes coughing. PGE 2 , similarly to PGE 1 , acts as a direct vasodilator by acting on smooth muscle to cause dilation of blood vessels.

In addition, PGE 2 inhibits platelet aggregation. PGE 2 also suppresses T cell receptor signaling and proliferation, and may play a role in resolution of inflammation. In addition, PGE 2 limits the immune response by preventing B-lymphocyte differentiation and their ability to present antigens.

Neurological effects

In response to physiologic and psychologic stress, prostaglandin E 2 (PGE 2 ) is involved in several inflammation and immunity pathways. As one of the most abundant prostaglandins in the body, PGE 2 is involved in almost all typical inflammation markers such as redness, swelling, and pain.

It regulates these responses through binding to G coupled protein prostaglandin E 2 receptors (EP 1 , EP 2 , EP 3 , and EP 4 ). The activation of these different EP receptors is dependent on the type of triggering stress stimuli and results in the corresponding stress response.

Activation of EP 1 via PGE 2 results in the suppression of impulse behaviors in response to psychological stress. PGE 2 is involved in regulating illness-induced memory impairment via activation of EP 2 . PGE 2 activation of EP 3 results in regulation of illness induced fever.

EP 4 is functionally similar to EP 2 and has also been shown in studies to have a role in hypothermia and anorexia. In addition to inflammatory effects, PGE 2 has been shown to have anti-inflammatory effects as well, due to its different actions on varying receptors.

Side effects

A common side effect of prostaglandin E 2 is its effect on gastrointestinal smooth muscle resulting in nausea, vomiting and diarrhea. Other side effects include headache, shivering, and chills. The suppository form of prostaglandin E 2 is associated with increased severity of these symptoms.

Fever is also a common side effect with use of prostaglandin E 2 . Administration of prostaglandin E 2 should be stopped if a person experiences side effects such as fever. The insert and gel forms have been shown to have minimal gastrointestinal effects, but are more associated with increase stimulation of the uterus as well as fetal distress.

Uterine hyperstimulation is effectively treated by stopping use of prostaglandin E 2 . Other monitoring parameters include sustained uterine contractions and fetal distress. In babies there may be decreased breathing and low blood pressure.

Care should be taken in people with asthma or glaucoma and it is not recommended in those who have had a prior C-section.

Mechanism of action

Prostaglandin E 2 (PGE 2 ) binds to G protein-coupled receptors (GPCRs) EP 1 , EP 2 , EP 3 , and EP 4 to cause various downstream effects to cause direct contractions in the myometrium. In addition, PGE 2 inhibits Na+ absorption within the Thick Ascending Limb (TAL) of the Loop of Henle and ADH-mediated water transport in collecting tubules. As a result, blockage of PGE 2 synthesis with NSAIDs can limit the efficacy of loop diuretics.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1372982572 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

14 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.